August 2012
-
The United States District Court for the District of Delaware has ruled that Liquidia’s Yutrepia treprostinil DPI would infringe claims contained in US patents 9,593,066 and 10,716,793, which cover United Therapeutics’ Tyvaso inhaled treprostinil; however,… Read more . . .
-
The European Patent Office (EPO) has granted Orexo a patent (EP 3962455B1) covering the company’s OX640 intranasal dry powder adrenaline, which is in Phase 1 development for the emergency treatment of anaphylaxis. According to the… Read more . . .
-
Aptar Pharma said that it has acquired US-based design firm Metaphase Design Group and will integrate the company into its subsidiary Noble, which Aptar acquired in 2019. Noble launched its Human Factors Plus (HF+) services… Read more . . .
-
Hikma Pharmaceuticals has launched Ryaltris olopatadine / mometasone nasal spray in the US, the company said. Hikma acquired US rights to Ryaltris in February 2020, and the FDA approved Glenmark’s NDA for the nasal spray… Read more . . .
-
According to Lupin, the MHRA has approved company’s Lutio tiotropium bromide inhalation powder, a generic version of Boehringer Ingelheim’s Spiriva Handihaler. The approval is the second for a Lupin OINDP in the UK; the MHRA… Read more . . .
-
Savara has announced the resignation of Badrul Chowdhury as Chief Medical Officer, effective September 9, 2022. Chowdhury, a former Director of the FDA’s Division of Pulmonary, Allergy, and Rheumatology Products, joined Savara as CMO in November… Read more . . .
-
Adherium has submitted a 510(k) application for use of its next generation Hailie inhaler monitoring sensor with Teva’s ProAir albuterol MDI and its generic albuterol HFA MDI, the company said. Recently, the company filed a… Read more . . .
-
Verona Pharma, which recently announced that a Phase 3 trial of its nebulized ensifentrine for the treatment of COPD met its primary endpoint, has announced the appointments of Matthew Casbon as VP of Sales, Marketing,… Read more . . .
-
According to Savara, the MHRA has granted Promising Innovative Medicine (PIM) designation to the company’s molgramostim inhaled recombinant human granulocyte-macrophage colony-stimulating factor (GM-CSF) for the treatment of autoimmune pulmonary alveolar proteinosis (aPAP). The PIM designation… Read more . . .
-
A US District Court has ordered Wockhardt subsidiary Morton Grove Pharmaceuticals “to stop manufacturing and distributing drugs alleged to be adulterated.” The Morton Grove facility manufactured fluticasone propionate nasal sprays in addition to other products.… Read more . . .
Featured event:
5th Annual Inhaled & Nasal Biologics | DNA Forum
5th Annual Inhaled & Nasal Biologics | DNA Forum
24th-25th September 2026, Cambridge, UK
Join us for a ground-breaking and insightful forum: Two days of cutting-edge talks and networking opportunities in this complex area of drug and vaccine development.
With renowned industry leaders who will share their insights and real-world case studies, our speakers will explore innovative formulation and delivery technologies and the rationale behind overcoming development challenges. Don’t miss out on this opportunity to learn more about key topics shaping the future of inhaled therapeutics.
Get online to see speakers announced so far. Registration is live – save your seat now!
Upcoming Events
Sponsored by Intertek,, hosts of
The Inhaled & Nasal Biologics | DNA Forum
Want information about upcoming OINDP-related events delivered directly to your inbox? click here
No events are found.